ADAMTS13 exerts a thrombolytic effect in microcirculation

• Published in: Thrombosis and haemostasis Vol. 108; no. 3; p. 527
• Main Authors: Crescente, Marilena, Thomas, Grace M, Demers, Melanie, Voorhees, Jaymie R, Wong, Siu Ling, Ho-Tin-Noé, Benoit, Wagner, Denisa D
• Format: Journal Article
• Language: English
• Published: Germany 01.09.2012
• Subjects: ADAM Proteins - pharmacology; ADAM Proteins - therapeutic use; ADAM Proteins - toxicity; ADAMTS13 Protein; Animals; Chlorides - toxicity; Computer Systems; Disease Models, Animal; Drug Evaluation, Preclinical; Ferric Compounds - toxicity; Fibrinolytic Agents - pharmacology; Fibrinolytic Agents - therapeutic use; Fibrinolytic Agents - toxicity; Hemorrhage - chemically induced; Humans; Male; Mice; Mice, Inbred C57BL; Microcirculation - drug effects; Microscopy - methods; Recombinant Proteins - pharmacology; Recombinant Proteins - therapeutic use; Recombinant Proteins - toxicity; Skin Window Technique; Thrombolytic Therapy - adverse effects; Tissue Plasminogen Activator - pharmacology; Tissue Plasminogen Activator - therapeutic use; Venous Thrombosis - chemically induced; Venous Thrombosis - drug therapy; Venules

Recombinant tissue plasminogen activator (r-tPA) is the drug of choice for thrombolysis, but it is associated with a significant risk of bleeding and is not always successful. By cleaving von Willebrand factor (VWF), the metalloprotease ADAMTS13 (a disintegrin-like and metalloprotease with thrombosp...